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Abstract
Purpose This phase I study was carried out to determine
the phase II recommended dose of tasisulam sodium (here-
after, tasisulam), a novel anticancer agent with a unique
mechanism of action.
Methods Tasisulam was administered intravenously,
every 21 days, in patients with refractory solid tumors
using a three-plus-three dose-escalation schema.
Results Fifty-three patients were enrolled; the Wrst 34
were treated with a Xat dose of tasisulam of up to 2,400 mg,
the dose level at which all three patients had dose-limiting
toxicity (DLT). Controlling for Cmax proved important to
reduce the risk of toxicity; therefore, we initially
focused on identifying which parameters explained Cmax
(end-of-infusion concentration) variability. Pharmacoki-
netic analysis indicated that Cmax negatively correlates with
lean body weight (LBW). Thus, the dosing regimen was
revised using a LBW-based algorithm targeting a speciWc
Cmax. A loading/chronic dose paradigm was then imple-
mented as pharmacokinetic results revealed a long terminal
half-life of tasisulam, likely because of its high-aYnity
albumin binding. Cmax-based dose escalation was stopped
at the 420-g/mL cohort, in which one of the 16 patients
had DLT (transient hepatic transaminase elevation); grade
3/4 hematologic toxicity was noted in later cycles in three
patients. Although response was not a primary objective,
33% of heavily pretreated patients with post-dose radiolog-
ical assessments had stable disease.
Conclusion Implementation of a novel targeted Cmax-
based dosing regimen allowed for the recommendation of a
phase II tasisulam dose (loading dose of 420 g/mL tar-
geted Cmax with all subsequent doses administered at 65%
of chronic dose given every 21 days) despite pharmacologi-
cal challenges posed by high albumin binding.
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Introduction
Tasisulam sodium (benzamide, N-[(5-bromo-2-thienyl)sul-
fonyl]-2,4-dichloro-, sodium salt; hereafter referred to as
tasisulam), an acylsulfonamide, is a member of a new class
of antineoplastic agents [1]. An in vitro, antitumor-screen-
ing analysis conducted by the National Cancer Institute
(NCI COMPARE analysis) [2] demonstrated a broad range
of activity for tasisulam in 60 tumor cell lines including
leukemia, melanoma, non-small cell lung (NSCLC), colon,
ovarian, renal, and breast cancers. In addition, the activity
proWle of tasisulam in the COMPARE analysis did not
match that of any other known anticancer compound [2],
which suggests a mechanism of action for tasisulam that is
distinct from currently available agents.
Preclinical in vitro studies indicate that tasisulam
induces apoptosis in cancer cells by the mitochondrial
(intrinsic) cell death pathway [3], and also induces a block
at the G2/M phase of the cell cycle. However, the precise
cellular or mitochondrial target that leads to the induction
of apoptosis remains unknown. Tasisulam has also demon-
strated anti-angiogenic activity in vitro (Lilly data on Wle).
In vivo pharmacokinetic studies in rats and dogs indi-
cate that tasisulam is metabolized primarily by the liver,
and has low total plasma clearance with a relatively long
half-life (approximately 10 h in rats and 20 h in dogs).
In vitro measurements also showed that tasisulam is
highly protein bound (»99%) in humans, mice, rats, and
dogs (Lilly data on Wle). In addition, there was preclinical
evidence of a correlation between the maximum plasma
concentration (Cmax) of tasisulam and toxicity (Lilly data
on Wle).
The broad spectrum of preclinical antitumor activity of
tasisulam and its potentially unique mechanism of action
prompted this phase I dose-escalation study in patients with
advanced or refractory solid tumors. The primary objective
of the study was to determine the recommended phase II
dose of tasisulam; secondary objectives were to character-
ize the toxicity and pharmacokinetic proWles of tasisulam,
and to discern whether there was any antitumor activity.
Patients and methods
Eligibility criteria
Patients ¸ 18 years of age with histologically or cytologi-
cally documented advanced and/or metastatic malignancy
for which no proven eVective therapy exists were eligible to
participate in this study. Patients were required to have a
performance status of 0 or 1 on the Eastern Cooperative
Oncology Group (ECOG) scale, adequate bone marrow
reserve, kidney and liver function. Discontinuation of all
the previous therapies (including chemotherapy, radiother-
apy, or other investigational therapy) at least 4 weeks
before study enrollment and recovery from all toxicities
were also required. Patients who had hematologic malig-
nancies or a history of central nervous system neoplasm or
who required palliative radiotherapy at study entry were
excluded from study participation.
Written informed consent was obtained from each
patient before study participation. The study was approved
by the institutional review board(s) of the participating
institutions, and was conducted according to applicable
laws and regulations, good clinical practices, and the ethi-
cal principles of the Declaration of Helsinki.
Treatment plan and dose-escalation schema
For the purpose of this open-label, single-arm, dose-esca-
lating, phase I study, tasisulam was supplied by Eli Lilly
and Company (Indianapolis, IN) in single-use, 20-mL glass
vials containing tasisulam sodium, sodium chloride, and
water or as a freeze-dried formulation in a 50-mL-vial
equivalent to 500 mg of base compound. Tasisulam sodium
was diluted in 500 mL of 0.9% sodium chloride, and was
stored at room temperature for up to 8 h. This compound
was administered as an intravenous infusion over 2 h
(§10 min) on day 1 of a 21-day cycle.
Dose escalation and the maximum tolerated dose (MTD)
were based on toxicity and pharmacokinetic results
observed in cycle 1. Dose-limiting toxicity (DLT) was deW-
ned as possibly drug-related grade ¸ 3 non-hematologic
toxicity (except for nausea/vomiting without maximal
symptomatic/prophylactic treatment and alopecia) accord-
ing to the NCI Common Toxicity Criteria (CTC) version
2.0 or grade 4 hematologic toxicity of >5 days duration.
Initially, dose escalation was based on a Xat-dose
escalation schema ranging from 100 to 2,400 mg (100,
200, 400, 660, 1,000, 1,400, 1,800, and 2,400 mg). Early
in the study, intrapatient dose escalation to the next
higher cohort was permitted if a patient completed two
cycles of treatment without a DLT; however, the toxici-
ties of these patients were not included in the DLT eval-
uation. The Xat-dose escalation schema was later revised
to one based on lean body weight (LBW; discussed fur-
ther in “Results”).
The dose-escalation schema followed a three-plus-three
design [4]. Per the protocol, if ¸2 patients in a cohort had
DLT, then the MTD was surpassed and dose escalation was
stopped. The MTD was then identiWed as the next lower
cohort in which less than two of six patients had DLT, but
if the dose exposure was nonlinear, patient recruitment was
allowed into additional cohorts between the highest cohort
reached and the previous cohort evaluated to identify the
recommended phase II dose.Cancer Chemother Pharmacol (2011) 68:1233–1241 1235
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Baseline and treatment assessments
Medical history, physical examination, performance status
assessment, and tumor measurement of palpable or visual
lesions were all carried out at baseline and at every cycle.
Complete blood counts, serum chemistry, and urinalysis
were performed at baseline, before each cycle, and post-
therapy. Twelve-lead electrocardiograms were conducted at
baseline, during cycle 1, and post-therapy. Clinically indi-
cated radiologic imaging (computerized tomography scan,
magnetic resonance imaging, or chest radiograph) was per-
formed at baseline and at every other cycle to assess
response to treatment. Tumor responses were followed and
recorded using Response Evaluation Criteria in Solid
Tumors (RECIST) [5]; however, the study was not
designed to assess treatment eYcacy.
Bioanalytical methods
Plasma samples containing ethylenediaminetetraacetic acid
(EDTA) were analyzed for total tasisulam concentrations
using two validated liquid chromatography-tandem mass
spectrometry (LC–MS/MS) methods. A dual-range method
(that is, high-range and low-range) was needed due to the
large peak to trough plasma concentrations observed. The
calibration range for the high-range method was 2.50–
500.0 g/mL, and for the low-range method, it was 0.025–
5.00 g/mL. Samples above the upper limit of quantiWca-
tion were diluted and reanalyzed to yield results within the
calibrated range. Samples below the lower limit of quantiW-
cation using the high-range method were reanalyzed using
the low-range method. Tasisulam and internal standard
were extracted from EDTA plasma by protein precipitation
using a 96-well plate format.
For the high-range method, accuracy (% relative error)
for the original validation ranged from ¡3.73 to 12.52% for
the intra-assay accuracy and between ¡1.93 and 8.36% for
the inter-assay accuracy. Precision (% relative standard
deviation) ranged from 1.18 to 6.72% for intra-assay
precision and between 2.095 and 7.27% for inter-assay
precision.
For the low-range method, accuracy (% relative error)
for the original validation ranged from ¡2.88 to 13.84% for
the intra-assay accuracy and between 5.77 and 7.69% for
the inter-assay accuracy. Precision (% relative standard
deviation) was between 2.38 and 11.54% for the intra-assay
precision and between 0.760 and 8.080% for the inter-assay
precision.
Pharmacokinetic evaluations
Blood samples were collected predose, 0.5, 1, 2 (end of
infusion), 2.25, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 168 h
(7 days) after the start of the infusion to evaluate the phar-
macokinetic parameters of tasisulam. In addition, EDTA
plasma samples (approximately 7 mL) were obtained pre-
dose from the Wrst 12 patients in the study to assess protein
binding. Pharmacokinetic parameters were computed by
standard noncompartmental methods using WinNonlin
Enterprise 5.0.1.
Statistical methods
Dose proportionality was assessed by Wtting the power
model to pharmacokinetic parameters against dose and
summarized using the methods described by Smith et al.
[6]. Body-size parameters were added to the power model
to determine which of these best explained the variability in
pharmacokinetic parameters. The choice was based on
selecting the model with the smallest Akaike Information
Criterion (AIC) [7] for those covariates that signiWcantly
reduced the underlying interpatient variability.
Results
Patient characteristics
This study was conducted at the H. Lee MoYtt Cancer Cen-
ter, Tampa, FL and the Memorial Sloan-Kettering Cancer
Center, New York, NY, in collaboration with Eli Lilly and
Company. From August 2003 to February 2007, 62 patients
were entered into the study and 53 received at least one
dose of tasisulam (seven patients did not meet enrollment
criteria and two withdrew consent). Patient demographics
are summarized in Table 1.
Dose-escalation
On the basis of preclinical toxicity and eYcacy testing
(Lilly data on Wle), tasisulam was administered as a Xat
dose, ranging from 100 to 2,400 mg, to 34 patients enrolled
in cohorts 1 through 9 (Table 2). DLTs were not observed
in patients enrolled in cohorts 1 through 6 (100–1,400 mg).
One of the three patients treated in cohort 7 (1,800 mg) was
discontinued from the study in cycle 1 because of tumor-
related spinal cord compression and was replaced; this
patient had a grade 3 DLT (diarrhea). Three additional
patients were then enrolled in this cohort (for a total of
seven patients), and no additional DLTs were observed. In
cohort 8 (2,400 mg), all three enrolled patients experienced
DLT. One patient with metastatic NSCLC and a history of
inXammatory colitis developed grade 3 stomatitis, grade 3
thrombocytopenia, and gastrointestinal bleeding, and later
developed grade 4 febrile neutropenia and fatal acute respi-
ratory distress syndrome (ARDS) in the setting of bilateral1236 Cancer Chemother Pharmacol (2011) 68:1233–1241
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pulmonary nodules and pleural eVusions. Another patient
developed a prolonged prothrombin time (16-day duration
without signiWcant bleeding) that was later attributed to an
interaction between tasisulam and the concomitantly
administered medication, warfarin. The third patient devel-
oped hemoptysis from a tracheostomy site and grade 3
bilateral pneumonia 3 days after administration of tasisu-
lam; the patient’s white blood cell count was 12.4 k/L and
platelet count was 159 k/L. Bronchoscopy was negative
for active bleeding, and no further hemoptysis was noted,
but secretions were considered consistent with alveolar
hemorrhage (grade 3 pulmonary hemorrhage). Because the
MTD had been surpassed at the 2,400-mg Xat-dose cohort,
three patients were enrolled at an intermediate Xat dose of
2,000 mg (cohort 9), and three additional patients were
enrolled at the 1,800-mg Xat dose (cohort 7). No additional
DLTs were observed.
One patient each in cohorts 7 and 9 had grade 4 hemato-
logic toxicity (thrombocytopenia/pancytopenia, respec-
tively) in cycle 2 that lasted at least 8 days in one patient,
suggesting the possibility of cumulative toxicity from the
accumulation of bound drug with repeated Xat dosing.
Pharmacokinetics
Of the 34 patients administered Xat doses of 100–2,400 mg
(cohorts 1–9), 33 had full pharmacokinetic proWles from
cycle 1. The analysis of pharmacokinetic data showed high
interpatient variability (Table 3), a low total plasma clear-
ance (approximately 0.03 L/h), a volume of distribution
that was likely limited to the distribution volume of albu-
min (approximately 9 L) [8], and a terminal elimination
half-life that corresponded to the turnover rate of albumin
(approximately 11 days) [9]. Values of Cmax increased less
than proportionately with dose, with coeYcients of varia-
tion of 22% after adjusting for dose (Fig. 1a). On the basis
of preclinical animal studies, in which the degree of Cmax
variability appeared to be associated with the risk of toxic-
ity (Lilly data on Wle), it was thought that controlling Cmax
variability in patients should reduce their risk of toxicity.
Therefore, the relationship between body size-related
parameters and Cmax was explored. LBW, which was calcu-
lated using an algorithm incorporating the patient’s height,
weight, and gender [10, 11], was identiWed as an important
cofactor that demonstrated a clear inverse relationship
between LBW and Cmax (Fig. 1b) and reduced the interpa-
tient variability of Cmax (from 22 to 13%) (Fig. 1c). Thus,
pharmacokinetic analysis revealed that the Cmax for tasisu-
lam (deWned as its concentration at the end of the 2-h infu-
sion) negatively correlated with the LBW of the patient.
This led to a change from the Xat-dose paradigm to a
LBW-based dosing paradigm targeting an individualized Cmax.
Phase II dose determination
Although the dose-escalation Wndings suggested an MTD
for tasisulam of approximately 2,000 mg, the signiWcant
interpatient and intrapatient variability of Cmax in the Xat-
dose cohorts and the high degree of albumin binding of
tasisulam (99.7–99.9%) suggested that the Xat-dosing
schema was unlikely to provide consistent drug exposure.
Table 1 Baseline patient demographics and disease characteristics
(N =5 3 )
ECOG Eastern Cooperative Oncology Group
a Patient was subsequently identiWed as having a performance status of
0 at baseline
b Non-small cell lung cancer (4 patients), adenocarcinoma (4 patients),
mesothelioma (4 patients), bronchioloalveolar carcinoma (1 patient),
and squamous (1 patient)
c Sarcoma (4 patients), uterine leiomyosarcoma (3 patients), osteo-
genic sarcoma (2 patients), and angiosarcoma (1 patient)
d Carcinoma (2 patients), thyroid carcinoma medullary (2 patients),
adenocarcinoma unknown primary (1 patient), adenoid cyst carcinoma
(1 patient), adrenal gland carcinoma (1 patient), and cholangiocarci-
noma (1 patient)
e One patient each: endometrial, endocervical, bladder, pancreas, pap-
illary adenocarcinoma, parotid gland, thymoma, and urothelium
f N = 52; prior medication(s) in one patient was not available
Sex, n (%)
Female 37 (69.8)
Male 16 (30.2)
Ethnicity, n (%)
Caucasian 47 (88.7)
Hispanic 3 (5.7)
African descent 2 (3.8)
East/Southeast Asian 1 (1.9)
Age, years
Median 57
Range 18–83
ECOG performance status, n (%)
0 28 (52.8)
1 22 (41.5)
22  ( 3 . 8 )
Unknowna 1 (1.9)
Tumor sites/histology, n (%)
Lungb 14 (26.4)
Sarcomac 10 (18.9)
Carcinomad 8 (15.1)
Ovarian 6 (11.3)
Melanoma 3 (5.7)
Colon 2 (3.8)
Breast 2 (3.8)
Othere 8 (15.1)
Median no. prior medications (range)f 6 (1–16)Cancer Chemother Pharmacol (2011) 68:1233–1241 1237
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These Wndings led to a change from Xat-dosing to a LBW-
based dosing paradigm targeting speciWc  Cmax values in
cohorts 10 and 11.
Because of the hematologic toxicity observed in later
cycles in cohorts 7 and 9, a loading dose was implemented
in cycle 1 followed by a lower chronic dose in subsequent
cycles in cohorts 10 and 11 to decrease the risk of drug
accumulation due to the relatively long terminal half-life of
tasisulam. The loading dose in cycle 1 for the LBW-based
cohorts targeted a Cmax of 400 g/mL (cohort 10) or
420 g/mL (cohort 11). The chronic doses were 70 and
65% of the loading doses for cohorts 10 and 11, respec-
tively. The initial LBW-based Cmax dose of 400 g/mL was
considered equivalent to the Xat doses that were considered
tolerable and showed antitumor activity (disease stabiliza-
tion).
None of the three patients enrolled in cohort 10 had DLT
(Table 2). In cohort 11, one of the six enrolled patients had
DLT (transient grade 3 hepatic transaminase elevation);
however, two of the six patients developed grade 3 or 4
hematologic toxicity in cycle 2, suggesting that escalation
to a higher targeted Cmax was unlikely to identify a dose
suitable for administration in phase II. Therefore, cohort 11
was expanded for further study. Of the 16 patients treated
in cohort 11, one patient had DLT, and three patients devel-
oped grade 3/4 thrombocytopenia/neutropenia in later
cycles (cycle 2 or more); thus, dose escalation was stopped.
The median number of treatment cycles in cohort 11 was
3 (range 1–14 cycles) (Table 2). Of the 16 patients in cohort
11, 14 completed at least two cycles, and eight completed at
least four cycles. Therefore, considering the heavily pre-
treated patient population and the tolerability of the 420 g/
mL Cmax targeted dose, this dose was recommended for
phase II study.
All of the 19 patients enrolled in cohorts 10 and 11 had
full pharmacokinetic proWles in cycle 1. The pharmacoki-
netic parameters (CL and Vss) were similar in these cohorts
compared with those of the Xat-dose cohorts 1–9; however,
comparison of the 1,800-mg Xat-dose group and the 420-
g/mL dose group revealed that the LBW-dosing schema
decreased the variability of AUC(0-1) and CL by approxi-
mately 50%, and the variability of Cmax from 28 to 19%
(Table 3). Comparisons of concentration versus time pro-
Wles for six pairs of patients, who were similar in their
LBW diVerence, indicated smaller diVerences between
Cmax values in patients dosed to a targeted Cmax of 420 g/
mL (Fig. 2a) compared with those given a Xat dose
(Fig. 2b).
Table 2 Dose-limiting toxicity (DLT) and treatment cycles administered by cohort
DLT was deWned as any drug-related grade ¸ 3 non-hematologic toxicity according to the NCI Common Toxicity Criteria (CTC) Version 2.0,
1998 (except for nausea/vomiting without maximal symptomatic/prophylactic treatment and alopecia) or grade 4 hematologic toxicity of >5 days
duration in cycle 1
G grade, PT/INR prothrombin time/international normalized ratio
a The elevated PT/INR was later attributed to the interaction of tasisulam and the concomitant medication, warfarin; the protocol was subsequently
amended to exclude patients who were actively receiving warfarin therapy as tasisulam and warfarin compete for the same albumin binding site
b An intermediate cohort of 2,000 mg (cohort 9) was explored. This cohort represented a dose between 1,800 mg (cohort 7) and 2,400 mg
(cohort 8)
c Three additional patients developed hematologic toxicity (grade 3/4 thrombocytopenia/neutropenia) in later cycles (¸cycle 2)
Cohort Dose No. DLTs/No. pts in cycle 1 Number cycles administered
Median (range) Total
1 100 mg 0/3 2 (2–4) 8
2 200 mg 0/3 2 (2–4) 8
3 400 mg 0/3 3 (2–4) 9
4 660 mg 0/3 2 (1–2) 5
5 1,000 mg 0/3 3 (2–4) 9
6 1,400 mg 0/3 2 (1–10) 13
7 1,800 mg 1/10 (G3 diarrhea) 2 (1–8) 28
8 2,400 mg 3/3 (G3 stomatitis + gastrointestinal bleeding
+ G4 febrile neutropenia; increased PT/INR 
for 16 daysa; G3 pneumonia
+ G3 pulmonary hemorrhage)
1 (1–2) 4
9 2,000 mgb 0/3 2 (2–4) 8
10 400 g/mL 0/3 2 (1–6) 9
11 420 g/mL 1/16 (transient grade 3 hepatic 
transaminase elevation)c
3 (1–14) 721238 Cancer Chemother Pharmacol (2011) 68:1233–1241
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Overall safety
The median number of cycles administered was 2 (range
1–18 cycles). The most common grade 3/4 toxicities con-
sidered possibly related to study drug were hematologic
(thrombocytopenia, anemia, and neutropenia; Table 4).
Fifteen patients received one or more transfusions (six red
blood cells; seven red blood cells and platelets; one red
blood cells, platelets, and plasma; and one plasma).
Of the six patients who died during the study, one patient
in cohort 8 died because of complications related to bone
marrow suppression (febrile neutropenia and ARDS during
cycle 1), and one patient in cohort 11 died because of an
outpatient cardiopulmonary arrest after receiving one cycle
of study drug (for which drug relatedness could not be ruled
out). An additional patient in cohort 11 died in cycle 2 from
NSCLC in the setting of post-obstructive pneumonia; the
patient had concurrent grade 2 neutropenia that was consid-
ered possibly related to study drug. All other patients died
because of causes related to their malignancy.
Six patients (cohort 7 or above) were discontinued from
the study because of adverse events considered possibly
related to study drug and/or complications: coagulopathy
with prolonged prothrombin time (patient had been receiv-
ing warfarin) associated with rectal bleeding; vaginal
bleeding; hypokalemia; thrombocytopenia; febrile neutro-
penia; and pneumonia and diVuse pulmonary hemorrhage.
Table 3 Summary of noncompartmental pharmacokinetic parameters
following a 2-h intravenous infusion of tasisulam
PK pharmacokinetic, CV coeYcient of variation, t1/2 terminal elimina-
tion half-life, Cmax maximum concentration (end-of-infusion concen-
tration), AUC(0–1) area under the concentration curve, CL clearance;
Vss steady-state volume of distribution, LBW lean body weight
a The minimum and maximum values are reported if N · 3; geometric
mean and CV% values are reported if N > 3, except for t1/2 for which
geometric mean and range are reported
b Ten patients (for 1,800 mg) and 15 patients (for 420 g/mL) were
used to calculate the geometric mean for Cmax
c Cmax is reported as received
d Variation in mg/kg as the relationship between LBW and Cmax is not
directly proportional
PK parameter Geometric mean (CV%)a
1,800 mg (n =8 ) 4 2 0g/mL 
targeted Cmax (n = 13)
t1/2 (h)a 213 (74–942) 269 (154–617)
Cmax (g/mL)b,c 322 (28) 359.83 (19)
AUC(0–1) (h g/mL) 70,900 (106) 98,100 (51)
CL (L/h) 0.026 (107) 0.024 (51)
Vss (L) 7.98 (29) 9.28 (24)
Arithmetic mean (CV%)
(Range)
LBW (kg) 53.8 (39)
(29.2–87.4)
48.6 (22)
(35.9–71.7)
Dose per kg LBW (mg/kg) 38.4 (39)
(20.6–61.7)
49.7 (8)d
(42.0–55.6)
Fig. 1 Results from assessment of dose proportionality showing Cmax
values increasing less than proportionately with dose (a); the relation-
ship between dose-normalized Cmax and LBW, demonstrating an
inverse relationship between LBW and Cmax (b); and dose proportion-
ality adjusted for LBW, showing reduced interpatient variability of
Cmax (c). Interpatient CV% in Cmax after accounting for each covariate
(cohorts 1–9): Cmax vs. dose: CV% = 22%; Cmax vs. dose + LBW:
CV% = 13%Cancer Chemother Pharmacol (2011) 68:1233–1241 1239
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EYcacy
Eight patients were discontinued from the study or died
before cycle-2 response assessment because of ARDS and
cardiopulmonary arrest (one patient, each); pneumonia and
pulmonary hemorrhage (one patient); lost to follow-up (one
patient); withdrawal of consent (one patient); and disease
progression (three patients, two of whom were objectively
conWrmed to have disease progression in follow-up visits).
Of the 45 patients assessed for response, there were no
objective responses; 25 had progressive disease, 15 had sta-
ble disease, and Wve had an unknown response because of
Fig. 2 Total plasma tasisulam (LY573636) concentrations using lean
body weight (LBW) and targeted Cmax dosing at 420 g/mL (a)a n d   Xat
dosing at 1,800 mg (b). The similar diVerences in LBW indicate that
the variability in pharmacokinetic parameters (both AUC and Cmax)
was reduced with LBW dosing1240 Cancer Chemother Pharmacol (2011) 68:1233–1241
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incomplete evaluation. However, Wve patients who
received extensive prior therapy (median 6, range 5–12
prior cancer treatments) for NSCLC (two patients), ovarian
cancer (two patients), or thymoma (one patient) received at
least 10 cycles of tasisulam (minimum of 7 months) before
disease progression.
Discussion
This is a Wrst-in-human, phase I, dose-escalation study of
tasisulam, a novel anticancer agent with a potentially
unique dual-faceted mechanism of action (apoptosis via
intrinsic mitochondrial death pathway and anti-angiogenic
activity). The recommended phase II dosing regimen for
tasisulam, administered as an intravenous 2-h infusion on
day 1 of 21-day cycles, was identiWed as a targeted Cmax of
420 g/mL (based on LBW). The most common toxicities
considered possibly related to study drug were those associ-
ated with bone marrow suppression, speciWcally, thrombo-
cytopenia and neutropenia. There was no grade 3/4 renal
toxicity or neuropathy. Grade 3 nausea, vomiting, and
stomatitis were observed in one patient each.
Extensive pharmacokinetic analysis of the Xat doses
(100–2,400 mg) administered to the Wrst 34 patients
revealed wide variability in tasisulam plasma concentrations
(Cmax). Preclinical animal studies suggested a correlation
between plasma Cmax and toxicity, which provided the
rationale for identifying covariates that aVected  Cmax in
humans. LBW was identiWed in this study as an important
covariate that signiWcantly reduced interpatient variability
in Cmax. These Wndings led to a novel dosing strategy using
LBW to achieve speciWc Cmax targets. Despite the novelty
of this dosing schema, dose calculation proved straightfor-
ward in this clinical study. Investigators entered patient
height, weight, sex, and cycle number into a CD–ROM-
based dosing calculator to determine the appropriate patient
dose.
Laboratory studies performed on human plasma and
serum conWrmed that approximately 99.7% of tasisulam is
bound to albumin and may be saturable across the pre-
sumed therapeutic dose range. Tasisulam showed bi-expo-
nential disposition with a median terminal elimination
half-life of approximately 11 days. Therefore, given the
extensive albumin binding of tasisulam and its long termi-
nal half-life, a loading dose in cycle 1 followed by a lower
chronic dose in subsequent cycles was implemented to
decrease the risk of a progressive rise in drug concentra-
tions in later cycles, which could increase the risk of satu-
rating albumin binding.
Although response was not a primary study objective, 15
of the 45 patients (33%) assessed for response at the end of
cycle 2 (28% of all patients dosed) had stable disease as the
best response despite having been heavily pretreated for
various refractory solid tumors. In addition, Wve patients
received at least 10 cycles of tasisulam before disease pro-
gression. The results of this trial and the Wndings from
another phase I trial evaluating tasisulam [12] led to the
initiation of phase II studies in relapsed/refractory solid
tumors, including NSCLC, platinum-resistant ovarian can-
cer [13], soft tissue sarcoma, and malignant melanoma [14].
Pharmacokinetic and safety data from these phase II studies
will provide additional opportunities to identify other
potentially important laboratory or pharmacokinetic factors
that could optimize dosing. In addition, preclinical and clin-
ical investigations continue in an eVort to provide addi-
tional insights on the mechanism of action of tasisulam.
In summary, analysis of pharmacokinetic and safety in
this phase I study allowed for the development of a novel
dosing algorithm for tasisulam, a Wrst-in-class anticancer
compound with a unique mechanism of action. Implemen-
tation of a LBW-based, targeted Cmax dosing regimen and a
loading/chronic dosing paradigm enabled the determination
of the phase II recommended dose for tasisulam, despite
pharmacological challenges posed by a high degree of
high-aYnity albumin binding and a long terminal half-life.
Table 4 CTC grade 3 and 4 possibly drug-related toxicities (N =5 3 )
CTC Common Toxicity Criteria (Version 2.0, 1998)
a Additional grade 3 toxicities observed in one patient include lympho-
penia, alkaline phosphatase, alanine transferase, asparate transferase,
abdominal pain/cramping, infection, nausea, vomiting, pleural eVu-
sion, and stomatitis/pharyngitis
b Platelet recovery times were available for two patients with platelet
count nadirs <15 £ 103/L, and were approximately 11 days for each
c Absolute neutrophil count (ANC) recovery times were available for
two patients with ANC nadirs of approximately 0.2 £ 103/L, and
were 12 and 14 days
d The prolonged prothrombin time of one patient was associated with
grade 3 rectal bleeding/hematochizia and that of the other was a DLT
without signiWcant bleeding; both patients were co-administered warfarin
Toxicity Grade 3a
n (%)
Grade 4
n (%)
Thrombocytopenia 7 (13.2) 3 (5.7)b
Anemia 5 (9.4) 1 (1.9)
Neutropenia 2 (3.8) 4 (7.5)c
Leukopenia 2 (3.8) 1 (1.9)
Hemorrhage/bleeding 4 (7.5) 0
Hypokalemia 4 (7.5) 0
Prothrombin time increasedd 2 (3.8) 0
Diarrhea 2 (3.8) 0
Epistaxis 2 (3.8) 0
Cardiopulmonary arrest 0 1 (1.9)
Adult respiratory distress syndrome 0 1 (1.9)
Febrile neutropenia 1 (1.9) 1 (1.9)
Pneumonia 1 (1.9) 0Cancer Chemother Pharmacol (2011) 68:1233–1241 1241
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Although this study was not designed to assess eYcacy, sta-
ble disease was observed in a reasonable proportion of
extensively pretreated patients with solid tumors, suggest-
ing the possibility of antineoplastic activity for tasisulam;
testing of this hypothesis is being pursued in currently
ongoing phase II clinical trials.
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